FI895045A0 - Menetelmä ihon kautta annettavan bunatsosiinia sisältävän farmaseuttisen valmisteen valmistamiseksi - Google Patents

Menetelmä ihon kautta annettavan bunatsosiinia sisältävän farmaseuttisen valmisteen valmistamiseksi

Info

Publication number
FI895045A0
FI895045A0 FI895045A FI895045A FI895045A0 FI 895045 A0 FI895045 A0 FI 895045A0 FI 895045 A FI895045 A FI 895045A FI 895045 A FI895045 A FI 895045A FI 895045 A0 FI895045 A0 FI 895045A0
Authority
FI
Finland
Prior art keywords
preparation
bunazosin
percutaneous administration
containing pharmaceutical
pharmaceutical preparation
Prior art date
Application number
FI895045A
Other languages
English (en)
Swedish (sv)
Other versions
FI92149B (fi
FI92149C (fi
Inventor
Mitsuhiro Yoshida
Hiroyuki Fujimori
Hidenori Asakawa
Masayoshi Kasai
Masanori Kayano
Shigemitsu Osawa
Original Assignee
Eisai Co Ltd
Sansho Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co Ltd, Sansho Co filed Critical Eisai Co Ltd
Publication of FI895045A0 publication Critical patent/FI895045A0/fi
Publication of FI92149B publication Critical patent/FI92149B/fi
Application granted granted Critical
Publication of FI92149C publication Critical patent/FI92149C/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
FI895045A 1988-11-11 1989-10-24 Menetelmä ihon kautta annettavan bunatsosiinia sisältävän farmaseuttisen valmisteen valmistamiseksi FI92149C (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP28542888 1988-11-11
JP63285428A JP2794022B2 (ja) 1988-11-11 1988-11-11 ブナゾシン或いはその塩類含有経皮適用製剤

Publications (3)

Publication Number Publication Date
FI895045A0 true FI895045A0 (fi) 1989-10-24
FI92149B FI92149B (fi) 1994-06-30
FI92149C FI92149C (fi) 1994-10-10

Family

ID=17691396

Family Applications (1)

Application Number Title Priority Date Filing Date
FI895045A FI92149C (fi) 1988-11-11 1989-10-24 Menetelmä ihon kautta annettavan bunatsosiinia sisältävän farmaseuttisen valmisteen valmistamiseksi

Country Status (11)

Country Link
US (1) US5041437A (fi)
EP (1) EP0368339B1 (fi)
JP (1) JP2794022B2 (fi)
AT (1) ATE90873T1 (fi)
AU (1) AU615115B2 (fi)
CA (1) CA2001574A1 (fi)
DE (1) DE68907312T2 (fi)
DK (1) DK559989A (fi)
ES (1) ES2057064T3 (fi)
FI (1) FI92149C (fi)
NO (1) NO176082C (fi)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0592569A1 (en) * 1991-07-03 1994-04-20 Sano Corporation Composition and method for transdermal delivery of diclofenac
US5900250A (en) * 1992-05-13 1999-05-04 Alza Corporation Monoglyceride/lactate ester permeation enhancer for oxybutnin
WO1995009006A1 (en) * 1993-09-29 1995-04-06 Alza Corporation Monoglyceride/lactate ester permeation enhancer
US5420106A (en) * 1994-03-22 1995-05-30 Bristol-Myers Squibb Company Method and composition having enhanced alpha-hydroxy acid skin permeation and retention
US5503843A (en) * 1994-04-22 1996-04-02 Flora Inc. Transdermal delivery of alpha adrenoceptor blocking agents
GB2301878A (en) * 1995-06-06 1996-12-18 Hardware & Systems Patents Ltd Ventilator:mounting
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
NZ513441A (en) † 1999-02-08 2004-01-30 Alza Corp Stable non-aqueous single phase viscous drug delivery vehicles comprising a polymer a solvent and a surfactant
US7179483B2 (en) 2000-04-26 2007-02-20 Watson Pharmaceuticals, Inc. Compositions and methods for transdermal oxybutynin therapy
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
CA2651855C (en) 2006-05-30 2011-08-02 Intarcia Therapeutics, Inc. Two-piece, internal-channel osmotic delivery system flow modulator
ES2422864T3 (es) 2006-08-09 2013-09-16 Intarcia Therapeutics, Inc Sistemas de liberación osmótica y unidades de pistón
PT2157967E (pt) 2007-04-23 2013-04-03 Intarcia Therapeutics Inc Formulações de suspensões de péptidos insulinotrópicos e suas utilizações
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
KR101823699B1 (ko) 2009-09-28 2018-01-30 인타르시아 세라퓨틱스 인코포레이티드 실질 항정상태 약물 전달의 신속 확립 및/또는 종결
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US10925639B2 (en) 2015-06-03 2021-02-23 Intarcia Therapeutics, Inc. Implant placement and removal systems
KR102574993B1 (ko) 2016-05-16 2023-09-06 인타르시아 세라퓨틱스 인코포레이티드 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
KR20190104039A (ko) 2017-01-03 2019-09-05 인타르시아 세라퓨틱스 인코포레이티드 Glp-1 수용체 효능제의 연속적인 투여 및 약물의 동시-투여를 포함하는 방법

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4377581A (en) * 1980-03-03 1983-03-22 Pfizer Inc. Chloro- and alkoxy-substituted-2,4-diaminoquinazolines
JPS58225009A (ja) * 1982-06-23 1983-12-27 Shionogi & Co Ltd コルチコステロイド外用製剤
JPS6122512A (ja) * 1984-07-06 1986-01-31 ヤマハ株式会社 ワイヤハ−ネス製造システム用コネクタ−配置ヘッド
JPS6169721A (ja) * 1984-09-13 1986-04-10 Kao Corp 抗真菌組成物
US4925837A (en) * 1984-09-14 1990-05-15 Synthelabo Pharmaceutical compositions
JPS61225122A (ja) * 1985-03-30 1986-10-06 Eisai Co Ltd キナツオリン系化合物含有組成物
JPH0735332B2 (ja) * 1986-02-25 1995-04-19 久光製薬株式会社 外用クリ−ム製剤
JP2521091B2 (ja) * 1986-06-18 1996-07-31 日研化学株式会社 カテコ−ルアミン類の外用製剤
JPH0816066B2 (ja) * 1986-07-18 1996-02-21 エーザイ株式会社 持続性薬効製剤
US4766842A (en) * 1987-04-29 1988-08-30 Jon Long Method and means for wave soldering of leads of an integrated circuit package
JP2563336B2 (ja) * 1987-06-01 1996-12-11 エーザイ株式会社 角膜透過促進点眼剤

Also Published As

Publication number Publication date
AU4384589A (en) 1990-05-17
US5041437A (en) 1991-08-20
FI92149B (fi) 1994-06-30
EP0368339B1 (en) 1993-06-23
DK559989D0 (da) 1989-11-09
FI92149C (fi) 1994-10-10
NO176082B (no) 1994-10-24
DK559989A (da) 1990-05-12
JPH02131426A (ja) 1990-05-21
AU615115B2 (en) 1991-09-19
DE68907312T2 (de) 1993-11-25
JP2794022B2 (ja) 1998-09-03
NO894465D0 (no) 1989-11-09
NO894465L (no) 1990-05-14
EP0368339A3 (en) 1990-12-19
CA2001574A1 (en) 1990-05-11
ES2057064T3 (es) 1994-10-16
DE68907312D1 (de) 1993-07-29
NO176082C (no) 1995-02-01
EP0368339A2 (en) 1990-05-16
ATE90873T1 (de) 1993-07-15

Similar Documents

Publication Publication Date Title
FI895045A0 (fi) Menetelmä ihon kautta annettavan bunatsosiinia sisältävän farmaseuttisen valmisteen valmistamiseksi
ATE15443T1 (de) Essbare, pharmazeutische zusammensetzungen und verfahren zur herstellung.
PH30120A (en) Stable pharmaceutical composition of fumagillol derivatives
IE861813L (en) New Polysaccharide Esters and their Salts
FR2547829B1 (fr) Compositions contenant des composes d'acides gras insatures et procede de stabilisation de tels composes
HUT52374A (en) Process for producing pharmaceutical compositions
WO1987004926A3 (en) Method of modifying the lipid structure of cell membranes and pharmaceutical compositions for use therein
DE3775754D1 (de) Alpha-halogenierte dicarbonsaeuren enthaltende pharmazeutische zusammensetzungen.
FI102457B1 (fi) Menetelmä probukolia sisältävän, parantuneen biosaatavuuden omaavan farmaseuttisen koostumuksen valmistamiseksi
FR2559151B1 (fr) Derives de l'arginine et sels d'addition d'acides correspondants pharmaceutiquement acceptables et compositions pharmaceutiques les contenant
ES8105691A1 (es) Procedimiento para separar d-acido 2-(6-metoxi-2-naftil)- propionico de una mezcla de d-y 1-acidos 2-(6-metoxi-2-naf- til)-propionicos o sus sales
NO883520L (no) Fremgangsmaate for fremstilling av et injeksjonspreparat.
IL82639A0 (en) Transdermal pharmaceutical composition
IE790754L (en) Substituted ethanolamines
FR2616149B1 (fr) Nouveau derive de l'acide benzo (b) thiophene - 7 carboxylique, son procede de preparation et les compositions pharmaceutiques qui le contiennent
HUT54371A (en) Process for producing macrolide compounds and pharmaceutical compositions containing them as active components
JPS5640607A (en) Drug composition
JPS57140783A (en) 1-benzyl-4-(4-(2-pyrimidinylamino)benzyl)-2, 3-dioxopiperazine derivative and its salt, their preparation, and carcinostatic agent containing the same
JPS5632436A (en) Prostaglandin analog and its preparation

Legal Events

Date Code Title Description
BB Publication of examined application
MM Patent lapsed
MM Patent lapsed

Owner name: SANSHO CO., LTD.

Owner name: EISAI CO., LTD.